医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

AirXpanders Raises $36.5 Million in Oversubscribed IPO; Strong Institutional Support; to List on ASX on Monday

2015年06月19日 AM06:00
このエントリーをはてなブックマークに追加


 

SYDNEY

AirXpanders Inc., a U.S.-based medical device company focused on the design, manufacture, sale and distribution of the AeroForm® tissue expander, has successfully raised AU$36.5 million following the close of its fully underwritten Initial Public Offering (IPO).

AirXpanders offered approximately 73 million CDIs in the company at AU $0.50 /CDI, with an indicative market capitalisation of approximately AU$113 million (on a fully-diluted basis).

Tissue expanders are used in breast reconstruction procedures following mastectomy to expand and stretch the skin and underlying muscle prior to the placement of a permanent breast implant. To date, tissue expansion has traditionally been a cumbersome and often traumatic process for which patients must typically attend the surgeon’s office regularly over a period of weeks or months to receive a series of saline injections through the breast and into a tissue expander.

By comparison, AeroForm® is a needle-free process that can be controlled by the patient herself (including at home or at work) through a wireless remote control unit that provides more efficient and less painful breast tissue expansion in a significantly shorter timeframe.

AeroForm® has been successfully used in more than 350 patients in clinical trials and commercial settings by a number of Australian and US leading breast reconstruction surgeons. The Company plans to build on the success of its recent market launch of AeroForm® in Australia by rapidly scaling its manufacturing and sales and marketing infrastructure.

Pending clearance from the FDA by the end of 2015, AirXpanders is preparing for its market launch of AeroForm® in the US from early next year.

“We are delighted with the strong response to this IPO. We’ve attracted the support of many domestic and international institutional investors as well as Australian retail investors,” said Scott Dodson, AirXpanders President and Chief Executive Officer.

“We believe that AeroForm® is the best innovation in tissue expander technology in decades and we are looking forward to making it available throughout Australia and the United States. Every woman deserves a comfortable, efficient breast reconstruction journey and the highest quality of life possible following a mastectomy, and we believe that AeroForm® clearly provides an attractive and compellingly better alternative for this important patient group in a significant market.”

View source version on businesswire.com: http://www.businesswire.com/news/home/20150618005464/en/

CONTACT

For more information please contact:
Company
Scott
Dodson, +1 (650)-390-9008
President & CEO
sdodson@airxpanders.com
or
Investor
and media relations

Buchan Consulting
Kyahn
Williamson, +61 (3) 9866 4722
kwilliamson@buchanwe.com.au

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Takeda to Highlight Broad Oncology Portfolio and Pipeline Data at the American Society of Clinical Oncology (ASCO) and the Congress of the European Hematology Association (EHA) Annual Meetings
  • Cerveau Technologies, Inc.与日本东京都老人综合研究所签订研究协议
  • 继美国和英国之后,中国向Personalis, Inc.签发ACE©技术专利,扩大了其在国际上的知名度
  • セルヴォー・テクノロジーズが日本の東京都健康長寿医療センター研究所と研究契約を締結
  • 国際的な食品・飲料企業の連合が、世界の供給食料から人工トランス脂肪酸を排除するための世界保健機関とResolve to Save Livesによる呼び掛けを支持